what are glp-1 agonists PDB-101: Molecule of the Month: Receptor America's Poison Centers - GLP-1

Obesity and insulin resistance sustain elevated circulating concentrations of pro-inflammatory cytokines including Tumour Necrosis Factor-alpha (TNF-), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) molecules that promote DNA damage, tumour angiogenesis, and immune evasion

Its important, however, to put this analysis into the proper context

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, et al

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE -/- mice

Researchers at Penn are already planning a multisite clinical trial that will evaluate whether GLP-1 therapy can reduce breast cancer incidence among high-risk women, including breast cancer survivors

This approval came after the SCALE Trial showed that high dose liraglutide not only better prevented progression from prediabetes to diabetes (as compared to placebo), but also had a threefold impact on weight loss